Recently, the ABL allosteric inhibitor ABL001 (Asciminib) which binds to the myristoyl binding site with a higher affinity than GNF-2/5 [148], has been evaluated in multicenter clinical trials in patients with CML and Ph + ALL (NCT02081378, NCT03292783) (Table 1). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.